Interim Analyses LANREL07484: Response to Treatment and Self-Reported Satisfaction in Symtoms in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with Lanreotide Autogel in South Africa

#2063

Introduction: An ongoing South African observational study in patients with symptomatic gastroenteropancreatic neuroendocrine tumours (GEP-NET)

Aim(s): To evaluate patient’s level of satisfaction and symptomatic response with diarrhoea and/or flushing when treated with Lanreotide Autogel over a six-month period. Quality of life, exposure to treatment and safety of Lanreotide Autogel in patients with GEP-NET treated with Lanreotide Autogel are also being measured

Materials and methods: This is a national, on-going, multi-centre, prospective observational cohort study involving 11 oncology sites in South Africa. The decision on treatment is made in accordance with routine clinical practice at the centre concerned. Patients are followed-up for 6 months (6M) after commencing treatment with Lanreotide Autogel. The data is collected prospectively at a baseline visit, 3 months (3M) and 6M after initiation. Response to treatment reported in this abstract is an interim analysis of the data available for 23 patients (9th June 2015 - 7th August 2017)

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Geldenhuys D

Authors: Geldenhuys D, Jacobs C, Rapoport B, Fourie S, Szpak W,

Keywords: gastroenteropancreatic neuroendocrine tumors, Flushing, Diarrhoea, Lanreotide Autogel,